Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.

Wei XuShenmiao YangKeshu ZhouLing PanZengjun LiJianfeng ZhouSujun GaoDaobin ZhouJianda HuRu FengHaiwen HuangMeng JiHaiyi GuoJane HuangWilliam NovotnyShibao FengJian-Yong Li

Published in: Journal of hematology & oncology (2020)

Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/. Retrospectively registered in ClinicalTrials.gov (NCT03206918) on July 2, 2017.

Keyphrases

chronic lymphocytic leukemia
diffuse large b cell lymphoma
healthcare
acute lymphoblastic leukemia
acute myeloid leukemia
mental health
multiple myeloma
lymph node metastasis
emergency department
squamous cell carcinoma
combination therapy
electronic health record